In:
Cancer, Wiley, Vol. 120, No. 6 ( 2014-03-15), p. 818-823
Abstract:
Using a population‐based cancer registry of men with de novo metastatic prostate cancer, the authors found no improvements in survival over time across the prostate‐specific antigen (PSA) era. After adjusting for differences in baseline covariates, there was even a suggestion of worsening overall survival for contemporary men compared with men diagnosed before the use of PSA screening.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1